BRPI0910282A2 - Composto oxadiazo-antraceno para o tratamento de diabetes - Google Patents

Composto oxadiazo-antraceno para o tratamento de diabetes

Info

Publication number: BRPI0910282A2
Authority: BR; Brazil
Prior art keywords: oxadiazo; anthracene compound; diabetes treatment; diabetes; treatment
Prior art date: 2008-03-07

Application number

BRPI0910282-5A

Other languages

English (en)

Inventor

Adnan M M Mjalli

Dharma Rao Polisetti

Thomas Scott Yokum

Kalpathy Santhosh

Mustafa Guzel

Christopher Behme

Stephen Thomas Davis

Original Assignee

Transtech Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-07

Filing date

2009-03-06

Publication date

2015-09-01

2009-03-06 Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc

2015-09-01 Publication of BRPI0910282A2 publication Critical patent/BRPI0910282A2/pt

Links

206010012601 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0910282-5A 2008-03-07 2009-03-06 Composto oxadiazo-antraceno para o tratamento de diabetes BRPI0910282A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3459908P	2008-03-07	2008-03-07
PCT/US2009/036333 WO2009111700A2 (en)	2008-03-07	2009-03-06	Oxadiazoanthracene compounds for the treatment of diabetes

Publications (1)

Publication Number	Publication Date
BRPI0910282A2 true BRPI0910282A2 (pt)	2015-09-01

Family

ID=41056666

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0910282-5A BRPI0910282A2 (pt)	2008-03-07	2009-03-06	Composto oxadiazo-antraceno para o tratamento de diabetes

Country Status (17)

Country	Link
US (7)	US7727983B2 (pt)
EP (1)	EP2262364B1 (pt)
JP (1)	JP5382952B2 (pt)
KR (1)	KR101616737B1 (pt)
CN (1)	CN101959405B (pt)
AU (1)	AU2009221722B2 (pt)
BR (1)	BRPI0910282A2 (pt)
CA (1)	CA2716664C (pt)
DK (1)	DK2262364T3 (pt)
EA (1)	EA018225B1 (pt)
ES (1)	ES2567451T3 (pt)
IL (1)	IL207570A (pt)
MA (1)	MA32175B1 (pt)
MX (1)	MX2010009752A (pt)
NZ (1)	NZ587343A (pt)
WO (1)	WO2009111700A2 (pt)
ZA (1)	ZA201006367B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7727983B2 (en)	2008-03-07	2010-06-01	Transtech Pharma, Inc.	Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) *	2009-03-30	2015-07-29	トランステック・ファーマ，エルエルシー	置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MX2013006768A (es)	2010-12-23	2013-07-22	Pfizer	Moduladores de receptor de glucagon.
WO2012096824A1 (en)	2011-01-12	2012-07-19	Transtech Pharma, Inc.	Phenylglyoxylic acid derivatives and their preparation and use
HRP20161177T1 (hr)	2011-02-08	2016-11-04	Pfizer Inc.	Modulator glukagonskog receptora
AU2012288493B2 (en)	2011-07-22	2015-08-06	Pfizer Inc.	Quinolinyl glucagon receptor modulators
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201491749A1 (ru) *	2012-03-22	2015-01-30	ТРАНСТЕК ФАРМА, ЭлЭлСи	Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
WO2014064215A1 (en)	2012-10-24	2014-05-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
SG10201704716XA (en) *	2013-01-17	2017-07-28	Vtv Therapeutics Llc	Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
EP3172199B1 (en) *	2014-07-25	2020-07-01	Celgene International II Sarl	Pyrimidine derivatives as glp-1 receptor modulators
US10426818B2 (en)	2015-03-24	2019-10-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) *	2016-09-26	2019-03-26	Chugai Pharmaceutical Co Ltd	مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (ja) *	2017-11-22	2019-05-31	第一三共株式会社	縮合三環化合物
EP3790549A1 (en)	2018-05-08	2021-03-17	vTv Therapeutics LLC	Therapeutic uses of glp1r agonists
CR20210341A (es)	2018-11-22	2021-11-25	Qilu Regor Therapeutics Inc	Agonistas de glp-ir y usos de los mismos
AU2020256647B2 (en) *	2019-04-12	2025-07-31	Qilu Regor Therapeutics Inc.	GLP-1R agonists and uses thereof
CA3157525A1 (en)	2019-10-25	2021-04-29	Gilead Sciences, Inc.	Glp-1r modulating compounds
US12459954B2 (en)	2020-04-01	2025-11-04	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh)	2020-04-01	2021-10-07	杭州中美华东制药有限公司	Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202144340A (zh)	2020-04-03	2021-12-01	大陸商江蘇恆瑞醫藥股份有限公司	稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
US20230348484A1 (en) *	2020-05-28	2023-11-02	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Method for preparing glp-1 receptor agonist free base
EP4159719A4 (en) *	2020-05-28	2024-07-17	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
AU2021306414B2 (en)	2020-09-01	2026-01-29	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4227299A4 (en)	2020-10-12	2025-04-09	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE
TWI912388B (zh) *	2020-10-14	2026-01-21	大陸商上海齊魯銳格醫藥研發有限公司	Ｇｌｐ-１ｒ促效劑的晶型及其用途
EP4247804A1 (en)	2020-11-20	2023-09-27	Gilead Sciences, Inc.	Polyheterocyclic glp-1 r modulating compounds
US20240246959A1 (en)	2020-11-27	2024-07-25	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Benzimidazole derivative and preparation method therefor and medical use thereof
CN116940561A (zh)	2021-03-22	2023-10-24	杭州中美华东制药有限公司	噻吩类glp-1受体激动剂及其用途
WO2022202864A1 (ja)	2021-03-24	2022-09-29	塩野義製薬株式会社	縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
PH12023552860A1 (en)	2021-04-21	2024-05-20	Gilead Sciences Inc	Carboxy-benzimidazole glp-1r modulating compounds
WO2022262615A1 (zh) *	2021-06-17	2022-12-22	杭州中美华东制药有限公司	蒽类化合物、其制备方法和医药用途
WO2022268152A1 (zh)	2021-06-24	2022-12-29	杭州中美华东制药有限公司	Glp-1受体激动剂及其组合物和用途
CN115521320B (zh) *	2021-06-25	2023-09-05	沈阳兴齐眼药股份有限公司	一种制备普拉洛芬的方法
US20260097037A1 (en)	2022-09-22	2026-04-09	Shionogi & Co., Ltd.	Fused ring compound having glp-1 receptor agonist effect
TW202521533A (zh)	2023-09-14	2025-06-01	香港商歌禮製藥(中國)有限公司	Glp-1r 激動劑及其治療方法
US12291530B1 (en)	2023-11-24	2025-05-06	Ascletis Pharma (China) Co., Limited	GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en)	2024-01-24	2025-07-31	Pfizer Inc.	Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en)	2024-03-08	2025-09-12	Annapurna Bio, Inc.	Methods for treating obesity and increasing weight loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6345270A (ja) *	1986-02-11	1988-02-26	Takeda Chem Ind Ltd	１，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
EP0233728A1 (en) *	1986-02-11	1987-08-26	Takeda Chemical Industries, Ltd.	1,4-Benzoxazine derivatives their production and use
CA2233888A1 (en) *	1995-10-06	1997-04-10	Ligand Pharmaceuticals Incorporated	Dimer-selective rxr modulators and methods for their use
JP2002534512A (ja) *	1999-01-15	2002-10-15	ノボノルディスクアクティーゼルスカブ	非ペプチドｇｌｐ−１アゴニスト
EP1236719A4 (en) *	1999-12-03	2003-06-25	Kyoto Pharma Ind	NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF, USE OF THESE COMPOUNDS IN MEDICINE
EP1125925A1 (en)	2000-02-15	2001-08-22	Applied Research Systems ARS Holding N.V.	Amine derivatives for the treatment of apoptosis
US20050222036A1 (en)	2000-08-24	2005-10-06	Thomas Jefferson University	Peptide compositions with effects on blood glucose
MXPA05010137A (es) *	2003-03-26	2005-11-16	Actelion Pharmaceuticals Ltd	Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
US7727983B2 (en) *	2008-03-07	2010-06-01	Transtech Pharma, Inc.	Oxadiazoanthracene compounds for the treatment of diabetes
US8501982B2 (en)	2010-06-09	2013-08-06	Receptos, Inc.	GLP-1 receptor stabilizers and modulators

2009
- 2009-03-06 US US12/399,504 patent/US7727983B2/en active Active
- 2009-03-06 CN CN200980108115.XA patent/CN101959405B/zh active Active
- 2009-03-06 KR KR1020107020688A patent/KR101616737B1/ko not_active Expired - Fee Related
- 2009-03-06 JP JP2010549910A patent/JP5382952B2/ja active Active
- 2009-03-06 DK DK09718287.7T patent/DK2262364T3/en active
- 2009-03-06 ES ES09718287T patent/ES2567451T3/es active Active
- 2009-03-06 BR BRPI0910282-5A patent/BRPI0910282A2/pt not_active Application Discontinuation
- 2009-03-06 CA CA2716664A patent/CA2716664C/en active Active
- 2009-03-06 NZ NZ587343A patent/NZ587343A/en not_active IP Right Cessation
- 2009-03-06 WO PCT/US2009/036333 patent/WO2009111700A2/en not_active Ceased
- 2009-03-06 EA EA201071045A patent/EA018225B1/ru not_active IP Right Cessation
- 2009-03-06 MX MX2010009752A patent/MX2010009752A/es active IP Right Grant
- 2009-03-06 EP EP09718287.7A patent/EP2262364B1/en active Active
- 2009-03-06 AU AU2009221722A patent/AU2009221722B2/en active Active
2010
- 2010-04-13 US US12/759,010 patent/US7790714B2/en active Active
- 2010-08-03 US US12/849,225 patent/US7906507B2/en active Active
- 2010-08-12 IL IL207570A patent/IL207570A/en active IP Right Grant
- 2010-08-31 US US12/872,580 patent/US8524708B2/en not_active Expired - Fee Related
- 2010-09-10 ZA ZA2010/06367A patent/ZA201006367B/en unknown
- 2010-09-30 MA MA33212A patent/MA32175B1/fr unknown
2013
- 2013-08-01 US US13/956,578 patent/US8703766B2/en not_active Expired - Fee Related
2014
- 2014-03-05 US US14/197,771 patent/US8933222B2/en active Active
- 2014-12-01 US US14/556,837 patent/US9120813B2/en active Active

Also Published As

Publication number	Publication date
ES2567451T3 (es)	2016-04-22
EP2262364B1 (en)	2016-03-02
US8524708B2 (en)	2013-09-03
EP2262364A2 (en)	2010-12-22
US8703766B2 (en)	2014-04-22
US20150087640A1 (en)	2015-03-26
US9120813B2 (en)	2015-09-01
IL207570A0 (en)	2010-12-30
EA018225B1 (ru)	2013-06-28
IL207570A (en)	2014-03-31
CA2716664C (en)	2016-10-11
CN101959405B (zh)	2014-07-02
JP5382952B2 (ja)	2014-01-08
EP2262364A4 (en)	2012-04-04
US20100197677A1 (en)	2010-08-05
NZ587343A (en)	2012-05-25
JP2011513431A (ja)	2011-04-28
US20100324033A1 (en)	2010-12-23
EA201071045A1 (ru)	2011-02-28
US20130317015A1 (en)	2013-11-28
WO2009111700A2 (en)	2009-09-11
MX2010009752A (es)	2010-09-30
US20110039837A1 (en)	2011-02-17
KR101616737B1 (ko)	2016-05-02
ZA201006367B (en)	2011-05-25
DK2262364T3 (en)	2016-03-21
US7727983B2 (en)	2010-06-01
CN101959405A (zh)	2011-01-26
AU2009221722B2 (en)	2014-12-18
CA2716664A1 (en)	2009-09-11
US20140187769A1 (en)	2014-07-03
WO2009111700A3 (en)	2010-03-04
MA32175B1 (fr)	2011-03-01
US8933222B2 (en)	2015-01-13
KR20100131455A (ko)	2010-12-15
HK1148435A1 (en)	2011-09-09
US7790714B2 (en)	2010-09-07
US7906507B2 (en)	2011-03-15
US20090306063A1 (en)	2009-12-10
AU2009221722A1 (en)	2009-09-11

Legal Events

Date	Code	Title	Description
2016-08-23	B25D	Requested change of name of applicant approved	Owner name: VTV THERAPEUTICS LLC (US)
2016-09-06	B25D	Requested change of name of applicant approved	Owner name: VTVX HOLDINGS I LLC (US)
2016-09-27	B25A	Requested transfer of rights approved	Owner name: VTV THERAPEUTICS LLC (US)
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-12-31	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2020-06-23	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
BRPI0910282A2 (pt)	2015-09-01	Composto oxadiazo-antraceno para o tratamento de diabetes
NO2024044I1 (no)	2024-10-08	Insulin icodec
LTPA2019009I1 (lt)	2019-04-10	C7-fluoru pakeisti tetraciklino junginiai
DK2288375T3 (da)	2012-05-21	Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt)	2015-12-29	compostos
BRPI0917675A2 (pt)	2015-12-01	compostos orgânicos para cura de ferida
DK2242759T3 (da)	2012-12-17	Forbindelser
SMT201500117B (it)	2015-07-09	Composti antibatterici
BRPI0908874A2 (pt)	2015-11-24	mecanismo de posicionamento de um leito
BRPI0716134A2 (pt)	2013-09-17	tratamento de combinaÇço para diabetes mellitus
BRPI0813670A2 (pt)	2014-12-30	Compostos para tratamento
BRPI0815042A2 (pt)	2015-02-10	Compostos de pirazol
BR112012000502A2 (pt)	2017-05-16	terapia de combinação para o tratamento de diabetes
DK2297162T3 (da)	2012-11-26	Forbindelser
BRPI0922884A2 (pt)	2018-11-06	compostos para tratamento de câncer
BRPI0916432A2 (pt)	2016-02-16	compostos
BRPI0821827A2 (pt)	2015-06-16	Derivados de beta-aminoácidos para tratamento de diabetes
BRPI0923592A2 (pt)	2016-01-26	composto
DK2271618T3 (da)	2014-06-16	Farmaceutiske forbindelser
DK2278899T3 (da)	2012-11-26	Bryggemekanisme
BRPI0911393A2 (pt)	2015-12-29	composto de 5-hidroxipirimidina-4-carboxamida
BRPI0920728A2 (pt)	2015-08-18	Composição estabilizada para tratamento de psoríase
DK2206698T3 (da)	2012-08-27	Ethynylindolforbindelser
HRP20160577T1 (hr)	2016-07-29	Liječenje osteoartritisa
PT2792662T (pt)	2016-07-07	Compostos de morfinano